Prosecution Insights
Last updated: October 04, 2026
Application No. 17/829,538

COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF

Final Rejection §103
Filed
Jun 01, 2022
Priority
Jan 30, 2017 — EU 17153751.7 +2 more
Examiner
RICCI, CRAIG D
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Givaudan S A
OA Round
6 (Final)
54%
Grant Probability
Moderate
7-8
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
620 granted / 1158 resolved
-6.5% vs TC avg
Strong +53% interview lift
Without
With
+52.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
77 currently pending
Career history
1217
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
41.7%
+1.7% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
20.5%
-19.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1158 resolved cases

Office Action

§103
DETAILED ACTION Notice of AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims The amendments filed 7/15/2026 have been entered. Response to Arguments Applicant’s arguments, filed 7/15/2026, have been fully considered. Applicant traverses the rejection of claims under 35 U.S.C. 103(a) as being unpatentable over Quellet et al (GB 2 528 480 published 1/27/2016 – provided in Applicant’s IDS submitted 6/01/2022; of record) in view of Ishida et al (US 2009/0171124; of record) and Wadsworth et al (J American Chem Soc 83:1733-1738, 1961; of record). Applicant first argues that “it is already questionable that a person of ordinary skill in the art would select” PNG media_image1.png 117 222 media_image1.png Greyscale (i.e., (2E,4Z)-4-benzylidene-2-methyldec-2-en-1-ol) from Quellet et al to prepare said compound (Applicant Arguments, Page 9). However, Applicant provides no reasoning as to this argument. As such, it is maintained that one of ordinary skill in the art desiring to practice the invention of Quellet et al would have found it obvious to prepare the compounds disclosed therein, including (2E,4Z)-4-benzylidene-2-methyldec-2-en-1-ol. Next, noting that “the rejection relies on a reconstruction of the Applicant’s process using disclosures selected from the separate references (namely Ishida and Wadsworth)”, Applicant argues that “such a reconstruction requires more than a showing that the individual reaction types were known in the art. Rather, it must be shown that a person of ordinary skill in the art would have been motivated to select the particular intermediate of formula C and the particular phosphonate derivative F recited in the claim, and would have had a reasonable expectation of success in obtaining the desired product by the claimed sequence of reactions” (Applicant Arguments, Page 10). The argument is not found persuasive. As discussed in the basis of the rejection, Ishida et al teach step (a) of coupling a compound of formula A with a compound of formula B to obtain a compound of formula C, specifically wherein the compound of formula C is “α-hexyl cinnamaldehyde” - PNG media_image2.png 116 152 media_image2.png Greyscale (see Paragraphs 0021 and 0048-0050, formulas (8), (9) and (10), i.e., “α-hexyl cinnamaldehyde”). Applicant, however, further argues that, although “Ishida... identifies α-hexyl cinnamaldehyde as one example... even if Ishida was considered to render obvious the preparation of the claimed aldehyde intermediate of formula C, this disclosure does not establish obviousness of the presently claimed process as a whole” and “[t]o address this problem, the Examiner relies on Wadsworth” (Applicant Arguments, Pages 10-11). Yet, as argued by Applicant, “Wadsworth merely discloses the general concept that phosphonate carbanions may react with aldehydes and ketones to form olefins... Wadsworth does not disclose an aldehyde intermediate of formula C, nor does it disclose a compound of formula (I)” (Applicant Arguments, Page 11). And, pointing to page 1734, left column, line 18, Applicant argues that “while Wadsworth discloses the use of cinnamaldehyde as a substrate in the disclosed olefination chemistry... the cinnamaldehyde employed therein bears a hydrogen atom in the α-position” as opposed to the “larger α-substituents” of instantly claimed formula C which “are significantly longer, more sterically hindered, and bulkier than... hydrogen” (Applicant Arguments, Page 11). Applicant’s arguments require one of ordinary skill in the art to limit the Horner-Wadsworth-Emmons reaction taught by Wadsworth et al solely to the exact compounds disclosed in the examples therein, which cannot be found persuasive. As indicated by the Court in KSR v. Teleflex (127 S,Ct. 1727 (2007)), the analysis under 35 USC 103 “need not seek out precise teachings directed to the specific subject matter of the challenged claim [but, instead] can take account of the inferences and creative steps that a person of ordinary skill in the art would employ”, emphasizing that “[a] person of ordinary skill is… a person of ordinary creativity, not an automaton”. Applicant additionally argues that “a person of ordinary skill, reading the cited references in their entirety, would not be motivated to modify Ishida in view of Wadsworth with a reasonable expectation of success and without undue experimentation” (Applicant Arguments, Page 12). In particular, Applicant argues that “[n]either Ishida nor Wadsworth provides a teaching that the specific α-substituted aldehydes of formula C would behave in the same manner as the unsubstituted cinnamaldehyde exemplified in Wadsworth, or that the claimed Horner-Wadsworth-Emmons reaction would proceed successfully to provide compounds of formula (I)” (Applicant Arguments, Page 12). The argument is not found persuasive. Again, it is not found persuasive that one of ordinary skill in the art would limit the limit the Horner-Wadsworth-Emmons reaction taught by Wadsworth et al solely to the exact compounds disclosed in the examples therein. Additionally, obviousness does not require absolute predictability, only a reasonable expectation of success of obtaining similar properties. In re O'Farrell, 853 F.2d 894 (Fed. Cir. 1988). Lastly, Applicant argues that “the present rejection relies upon first identifying the target compounds of the present application and then reconstructing a synthetic route thereto by selecting the specific aldehyde intermediate from Ishida and combining it with the generally disclosed chemistry of Wadsworth. The proposed combination is therefore not derived from the teachings of the prior art itself, but only becomes apparent with knowledge of the Applicants' invention and is thus based on hindsight” (Applicant Arguments, Page 12). In response to Applicant’s argument that the examiner’s conclusion of obviousness is based upon improper hindsight reasoning, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the Applicant’s disclosure, such a reconstruction is proper. See In re McLaughlin, 443 F.2d 1392 (CCPA 1971). In the instant case, the rejection of claims takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the Applicant’s disclosure. As such, Applicant’s argument is not found persuasive. For all the foregoing reasons, Applicant’s arguments are not found persuasive. The rejection of claim 25 is MAINTAINED. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim 25 is MAINTAINED rejected under 35 U.S.C. 103(a) as being unpatentable over Quellet et al (GB 2 528 480 published 1/27/2016 – provided in Applicant’s IDS submitted 6/01/2022; of record) in view of Ishida et al (US 2009/0171124; of record) and Wadsworth et al (J American Chem Soc 83:1733-1738, 1961; of record). Claim 25 is drawn to a process for the preparation of a compound of formula (I), which embraces the following compound species PNG media_image1.png 117 222 media_image1.png Greyscale wherein R1 is C1 alkyl; R2 is C6 alkyl; R3-R7 are H; and X is CH2OH; the method comprising: (a) coupling a compound of formula A with a compound of formula B, thereby obtaining a compound of formula C, wherein: the compound of formula A is: PNG media_image3.png 120 106 media_image3.png Greyscale the compound of formula B is: PNG media_image4.png 57 60 media_image4.png Greyscale the compound of formula C is: PNG media_image5.png 112 137 media_image5.png Greyscale (b) contacting the compound of formula C with a phosphonate derivative F thereby obtaining a compound of formula (I), wherein: the phosphonate derivative F is: PNG media_image6.png 96 126 media_image6.png Greyscale Quellet et al teaches the instantly claimed compound of formula (I) (i.e., (2E,4Z)-4-benzylidene-2-methyldec-2-en-1-ol (Page 4, Line 16)). However, Quellet et al does not teach methods for preparing said compound. Yet, it would have been obvious to prepare the compound of Quellet et al as claimed based further on Ishida et al and Wadsworth et al as follows: FIRST, Ishida et al teach step (a) of coupling a compound of formula A with a compound of formula B, thereby obtaining a compound of formula C. In particular, Ishida et al teach coupling the compound R1-CHO (Formula I) with R2-CHO (Formula II) – wherein R1 and R2 can be “a linear or branched alkyl group having 1 to 20 carbon atoms… [and] an aromatic ring structure-containing group having 6 to 20 carbon atoms” (Paragraph 0021) and which read on instant formulas A and B – to provide PNG media_image7.png 69 158 media_image7.png Greyscale (Formula III-b) (Paragraph 0021) which reads on instant formula C. Even more specifically, Ishida et al teach: coupling the compound PNG media_image8.png 76 108 media_image8.png Greyscale (Paragraphs 0045 and 0048, formula (6), i.e., a compound of Formula I as defined by Ishida et al which reads on a compound of formula A as instantly claimed (see also Paragraph 0027: “[e]xamples of the aldehyde compounds I and II used as the raw aldehyde compound in the present invention include… benzaldehyde” – i.e., PNG media_image8.png 76 108 media_image8.png Greyscale )) with the compound PNG media_image9.png 49 90 media_image9.png Greyscale (Paragraph 0045, formula (2) i.e., a compound of Formula II as defined by Ishida et al which reads on a compound of formula B as instantly claimed) to provide PNG media_image10.png 84 163 media_image10.png Greyscale (Paragraph 0045, formula (7) which reads on a compound of formula C as instantly claimed (see also Paragraph 0050: “[e]xamples of the α,β-unsaturated aldehyde compounds produced by the condensation reaction II… include… α-methyl cinnamaldehyde” – i.e., PNG media_image10.png 84 163 media_image10.png Greyscale – as well as “a-hexyl cinnamaldehyde” – i.e., PNG media_image2.png 116 152 media_image2.png Greyscale ). And it is evident from Ishida et al that utilizing PNG media_image11.png 83 137 media_image11.png Greyscale (i.e., in place of PNG media_image9.png 49 90 media_image9.png Greyscale ) would provide said PNG media_image2.png 116 152 media_image2.png Greyscale (see, e.g., Paragraphs 0021 and 0048-0050, formulas (8), (9) and (10), i.e., “a-hexyl cinnamaldehyde”). And SECOND, Wadsworth et al teach step (b2) of contacting a compound of formula C with a phosphonate derivative F, thereby obtaining a compound of instant formula (I). In particular, Wadsworth et al teach contacting a compound PNG media_image12.png 52 132 media_image12.png Greyscale (i.e., a compound of formula C as instantly claimed) with a compound having the following structure PNG media_image13.png 108 174 media_image13.png Greyscale (i.e., a phosphonate derivative F as instantly claimed) results in a compound having the following structure PNG media_image14.png 90 194 media_image14.png Greyscale (i.e., a compound of formula (I) as instantly claimed) via Honer-Wadsworth-Emmons (HWE) reaction (Page 1733, Column 1). As such, an ordinarily skilled artisan, desiring to synthesize the compound PNG media_image1.png 117 222 media_image1.png Greyscale taught by Quellet et al (Page 4, Line 16), would have found it obvious to contact PNG media_image2.png 116 152 media_image2.png Greyscale – the compound of formula C which also entails a compound having the general structure PNG media_image12.png 52 132 media_image12.png Greyscale – with PNG media_image15.png 162 198 media_image15.png Greyscale – the compound PNG media_image13.png 108 174 media_image13.png Greyscale which also entails a phosphonate derivative F – to provide said title compound PNG media_image1.png 117 222 media_image1.png Greyscale via Honer-Wadsworth-Emmons (HWE) reaction, based further on Wadsworth et al. In view of all of the foregoing, claim 25 is rejected as prima facie obvious. Claim Objections Claim 32 is MAINTAINED rejected as depending from a rejected base claim. Conclusion No new ground(s) of rejection are presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CRAIG D RICCI whose telephone number is (571) 270-5864. The examiner can normally be reached on Monday through Thursday, and every other Friday, 7:30 am - 5:00 pm ET. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bethany Barham can be reached on (571) 272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CRAIG D RICCI/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Show 9 earlier events
Feb 13, 2025
Response after Non-Final Action
Jun 11, 2025
Final Rejection mailed — §103
Sep 25, 2025
Response after Non-Final Action
Oct 08, 2025
Request for Continued Examination
Oct 09, 2025
Response after Non-Final Action
Mar 20, 2026
Non-Final Rejection mailed — §103
Jul 15, 2026
Response Filed
Sep 10, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746306
HYALURONIC ACID DERIVATIVE AND USE THEREOF
4y 3m to grant Granted Sep 29, 2026
Patent 12714103
PLANT DISEASE CONTROL COMPOSITION AND PLANT DISEASE CONTROL METHOD
4y 1m to grant Granted Aug 25, 2026
Patent 12715848
PROCESS FOR THE DIASTEREOMERICALLY PURE PREPARATION OF DL/LD-METHIONYLMETHIONINE
3y 2m to grant Granted Aug 25, 2026
Patent 12715879
QUINAZOLINE-4(3H)-ONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2
2y 11m to grant Granted Aug 25, 2026
Patent 12708616
COMPOSITIONS AND METHODS OF TREATING AGE-RELATED RETINAL DYSFUNCTION
3y 7m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

7-8
Expected OA Rounds
54%
Grant Probability
99%
With Interview (+52.7%)
3y 3m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1158 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month